A recent large observational study suggests that GLP-1 receptor agonist (GLP-1RA) medications — widely used for type 2 diabetes and increasingly for weight loss — may be linked with a higher rate of taste and smell disturbances. However, experts say such side effects do not appear to be common, and the benefits of these medicines for weight and metabolic health generally outweigh the possible sensory changes.
What the study found
Researchers analyzed medical records from the TriNetX Global Collaborative Network, covering more than 170 health institutions and including two groups of adults diagnosed with type 2 diabetes. Each group had over 430,000 people with no prior history of smell or taste problems; both cohorts were roughly 55% female with an average age near 57.
One group had been prescribed a GLP-1 medication after diagnosis, while the comparison group received other diabetes treatments but no GLP-1s. Follow-up extended from three months to up to two years after stopping GLP-1 therapy.
During the study window, taste disturbances were recorded in 769 people in the GLP-1 group versus 445 in the non‑GLP-1 group. Smell disturbances were recorded in 649 GLP-1 users versus 316 in the control group. The investigators suggested these effects could be related to GLP-1 activity in the nervous system, potentially involving the olfactory bulb or other chemosensory pathways.
What experts say
Clinicians not involved in the study noted several caveats. The research is observational, so it shows an association but cannot prove that GLP-1 drugs cause smell or taste loss. Several physicians reported that they have not seen widespread reports of such problems among their patients.
One bariatric surgeon and weight‑loss program director said he rarely hears complaints about impaired smell or taste and emphasized that the advantages of reaching a healthier weight usually outweigh these sensory issues. Another clinical medicine professor pointed out that if a medication is suspected of causing dysfunction, stopping the drug is a straightforward remedy to consider with a clinician.
Possible explanations and context
GLP-1 is a hormone also present in parts of the nervous system, so it’s biologically plausible that GLP-1RAs could affect sensory pathways. Weight loss itself can change taste and smell perception, and there are many other causes of temporary or permanent sensory changes, including viral and bacterial infections, allergies, aging, diabetes, dental problems, and certain medications.
Smell and taste are important for nutrition, safety (for instance, detecting smoke or gas), social interactions, and emotional memory. In the U.S., roughly 12% of people have some degree of smell dysfunction, and nearly 20% of people over 40 report taste alterations — so background rates of these problems are not trivial.
Limitations and takeaways
Because this was an observational analysis of medical records, it cannot establish causation. Sensory changes are multifactorial and may relate to weight loss, underlying health conditions such as diabetes, or other drugs, not only GLP-1 therapy. Also, not everyone who experiences mild changes seeks medical attention or has those changes recorded in their chart, so true rates are uncertain.
Clinicians recommend balancing risks and benefits. For many patients, the metabolic, cardiovascular, and weight-loss benefits of GLP-1 drugs are substantial and may outweigh a potential risk of temporary smell or taste disturbance. If someone does notice a change in smell or taste after starting a GLP-1 medication, discussing it with the prescribing clinician is appropriate — options include monitoring, adjusting therapy, or stopping the drug if the symptom is clearly linked and troublesome.
Practical advice
– Be aware of changes: pay attention to appetite, flavor perception, and ability to detect odors after starting any new medication.
– Report symptoms: tell your healthcare provider if you notice worsening or new smell or taste problems so they can evaluate possible causes and decide on next steps.
– Don’t assume causation: your clinician will consider other explanations (infections, dental issues, aging, diabetes-related changes, other medications) before attributing symptoms to a GLP-1 drug.
– Expect possible reversibility: temporary sensory changes from weight loss or medications often improve once weight stabilizes or the drug is discontinued, though recovery can vary.
Bottom line
Large-scale records-based research has found an association between GLP-1 therapy and higher recorded rates of smell and taste disturbance. The finding warrants further research and monitoring, but current expert opinion is that these sensory effects appear uncommon and should not generally deter people from taking GLP-1 medications when clinically indicated. If you experience bothersome changes in smell or taste while taking one of these drugs, discuss it with your healthcare provider to weigh options and next steps.